Applying a Decade of Topoisomerase ADC Experience to Build the Next Generation of Payloads
- Distil the most important translational and clinical lessons from the widespread adoption of topoisomerase I payloads across multiple tumor settings
- Analyze which resistance mechanisms could have been anticipated and which only emerged through large-scale clinical use, informing more effective development strategies moving forward
- Translate real-world experience into actionable guidance for designing nextgeneration topo payloads and identifying orthogonal mechanisms capable of addressing resistant patient populations